BR0008276A - Combinações de formoterol e propionato de fluticasona para asma - Google Patents
Combinações de formoterol e propionato de fluticasona para asmaInfo
- Publication number
- BR0008276A BR0008276A BR0008276-7A BR0008276A BR0008276A BR 0008276 A BR0008276 A BR 0008276A BR 0008276 A BR0008276 A BR 0008276A BR 0008276 A BR0008276 A BR 0008276A
- Authority
- BR
- Brazil
- Prior art keywords
- formoterol
- fluticasone propionate
- asthma
- combinations
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Abstract
Patente de Invenção: "COMBINAçõES DE FORMOTEROL E PROPIONATO DE FLUTICASONA PARA ASMA". Uma composição farmacêutica que compreende (A) formoteroL ou um sal do mesmo ou um solvato de formoterol ou o referido sal farmaceuticamente aceitável e (B) propionato de fluticasona, adequado para ser utilizado no tratamento de doenças inflamatórias ou obstrutivas das vias aéreas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9903759.0A GB9903759D0 (en) | 1999-02-18 | 1999-02-18 | Organic compounds |
PCT/EP2000/001270 WO2000048587A1 (en) | 1999-02-18 | 2000-02-16 | Combinations of formoterol and fluticasone propionate for asthma |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0008276A true BR0008276A (pt) | 2001-11-06 |
Family
ID=10848051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0008276-7A BR0008276A (pt) | 1999-02-18 | 2000-02-16 | Combinações de formoterol e propionato de fluticasona para asma |
Country Status (32)
Country | Link |
---|---|
US (4) | US20020103260A1 (pt) |
EP (1) | EP1152753B1 (pt) |
JP (1) | JP2002537249A (pt) |
KR (2) | KR20070104955A (pt) |
CN (1) | CN1339965A (pt) |
AR (1) | AR022609A1 (pt) |
AT (1) | ATE266393T1 (pt) |
AU (1) | AU758999B2 (pt) |
BR (1) | BR0008276A (pt) |
CA (1) | CA2368537A1 (pt) |
CO (1) | CO5140098A1 (pt) |
CZ (1) | CZ20012976A3 (pt) |
DE (1) | DE60010662T2 (pt) |
DK (1) | DK1152753T3 (pt) |
ES (1) | ES2220411T3 (pt) |
GB (1) | GB9903759D0 (pt) |
HK (1) | HK1042429A1 (pt) |
HU (1) | HUP0200852A3 (pt) |
ID (1) | ID29437A (pt) |
IL (1) | IL144061A (pt) |
MY (1) | MY126768A (pt) |
NO (1) | NO20013987D0 (pt) |
NZ (1) | NZ513526A (pt) |
PE (1) | PE20001545A1 (pt) |
PL (1) | PL349856A1 (pt) |
PT (1) | PT1152753E (pt) |
RU (1) | RU2249454C2 (pt) |
SK (1) | SK11842001A3 (pt) |
TR (1) | TR200102110T2 (pt) |
TW (1) | TWI229601B (pt) |
WO (1) | WO2000048587A1 (pt) |
ZA (1) | ZA200105391B (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
AU7026800A (en) | 1999-09-11 | 2001-04-17 | Glaxo Group Limited | Pharmaceutical formulation of fluticasone propionate |
GB2392915B (en) * | 1999-09-11 | 2004-04-28 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
GB2388843B (en) * | 1999-09-11 | 2004-03-03 | Glaxo Group Ltd | A metered dose inhaler containing a pharmaceutical formulation of fluticasone propionate |
US20030026766A1 (en) * | 2000-04-13 | 2003-02-06 | Mark Sanders | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
GB0009591D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical combinations |
GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
FI20002216A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
MXPA03007017A (es) * | 2001-02-06 | 2004-09-13 | Innovata Biomed Ltd | Medicamentos. |
GB0106031D0 (en) * | 2001-03-12 | 2001-05-02 | Glaxo Group Ltd | Use |
CZ301676B6 (cs) * | 2001-03-30 | 2010-05-19 | Jagotec Ag | Farmaceutický suspenzní aerosolový prípravek pro inhalaci a použití soli karboxylové kyseliny |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US7931022B2 (en) | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
JP2005523268A (ja) † | 2002-02-04 | 2005-08-04 | グラクソ グループ リミテッド | グルココルチコイドおよびβ2−アドレナリン受容体アゴニストを含む吸入用製剤 |
EP1757281A3 (en) * | 2002-02-04 | 2009-07-15 | Glaxo Group Limited | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
AU2003269989B8 (en) * | 2002-08-21 | 2009-11-12 | Norton Healthcare Ltd. | Inhalation composition |
JP4744876B2 (ja) * | 2002-08-21 | 2011-08-10 | ノートン・ヘルスケアー リミテッド | 乾燥粉末吸入組成物の製造方法 |
GB0219511D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
US20050158248A1 (en) * | 2002-08-21 | 2005-07-21 | Xian-Ming Zeng | Method of preparing dry powder inhalation compositions |
AU2003263717A1 (en) * | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
SE527189C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel |
SE526850C2 (sv) * | 2003-06-19 | 2005-11-08 | Microdrug Ag | Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd |
SE526509C2 (sv) * | 2003-06-19 | 2005-09-27 | Microdrug Ag | Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd |
SE527200C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av formaterol och fluticason |
SE527069C2 (sv) * | 2003-06-19 | 2005-12-13 | Mederio Ag | Förfarande och anordning för administrering av läkemedelspulver |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0617171D0 (en) * | 2006-08-31 | 2006-10-11 | Generics Uk Ltd | Novel compositions and methods |
WO2008137446A1 (en) * | 2007-05-03 | 2008-11-13 | Trustees Of Boston University | Methods and compositions for the treatment of respiratory disease |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
AR076621A1 (es) * | 2009-05-29 | 2011-06-22 | Pearl Therapeutics Inc | Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador |
GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
WO2011093811A2 (en) * | 2010-01-29 | 2011-08-04 | Mahmut Bilgic | Pharmaceutical preparations comprising formoterol and fluticasone |
MX2013004137A (es) | 2010-10-12 | 2013-07-29 | Cipla Ltd | Composicion farmaceutica. |
EA201490991A1 (ru) * | 2011-05-17 | 2014-09-30 | Перл Терапьютикс, Инк. | Композиции, способы и устройства для респираторной доставки двух или более активных средств |
JP2015512929A (ja) * | 2012-04-11 | 2015-04-30 | シプラ・リミテッド | 医薬組成物 |
CN105188679B (zh) | 2013-03-15 | 2018-10-16 | 珍珠治疗公司 | 用于微粒晶体材料的状态调节的方法和系统 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL95590A (en) * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
ATE213946T1 (de) * | 1991-12-18 | 2002-03-15 | Formoterol und budesonide enthaltende zusammensetzung | |
GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
JP2001511160A (ja) * | 1997-02-05 | 2001-08-07 | ヤゴ リサーチ アクチェンゲゼルシャフト | 医学用エアゾール配合物 |
PL192441B1 (pl) * | 1997-03-20 | 2006-10-31 | Schering Corp | Sposób wytwarzania aglomeratów i postać dawkowania środka farmakologicznie aktywnego |
-
1999
- 1999-02-18 GB GBGB9903759.0A patent/GB9903759D0/en not_active Ceased
-
2000
- 2000-01-27 TW TW089101371A patent/TWI229601B/zh not_active IP Right Cessation
- 2000-02-11 CO CO00009234A patent/CO5140098A1/es unknown
- 2000-02-16 CZ CZ20012976A patent/CZ20012976A3/cs unknown
- 2000-02-16 AU AU29115/00A patent/AU758999B2/en not_active Ceased
- 2000-02-16 WO PCT/EP2000/001270 patent/WO2000048587A1/en not_active Application Discontinuation
- 2000-02-16 HU HU0200852A patent/HUP0200852A3/hu unknown
- 2000-02-16 CA CA002368537A patent/CA2368537A1/en not_active Abandoned
- 2000-02-16 PL PL00349856A patent/PL349856A1/xx not_active Application Discontinuation
- 2000-02-16 PE PE2000000119A patent/PE20001545A1/es not_active Application Discontinuation
- 2000-02-16 AR ARP000100659A patent/AR022609A1/es unknown
- 2000-02-16 DK DK00907572T patent/DK1152753T3/da active
- 2000-02-16 KR KR1020077024082A patent/KR20070104955A/ko active Search and Examination
- 2000-02-16 DE DE60010662T patent/DE60010662T2/de not_active Revoked
- 2000-02-16 AT AT00907572T patent/ATE266393T1/de not_active IP Right Cessation
- 2000-02-16 ID IDW00200101675A patent/ID29437A/id unknown
- 2000-02-16 EP EP00907572A patent/EP1152753B1/en not_active Revoked
- 2000-02-16 KR KR1020017010434A patent/KR20010102205A/ko active Search and Examination
- 2000-02-16 JP JP2000599379A patent/JP2002537249A/ja active Pending
- 2000-02-16 CN CN00803855A patent/CN1339965A/zh active Pending
- 2000-02-16 IL IL14406100A patent/IL144061A/xx not_active IP Right Cessation
- 2000-02-16 ES ES00907572T patent/ES2220411T3/es not_active Expired - Lifetime
- 2000-02-16 PT PT00907572T patent/PT1152753E/pt unknown
- 2000-02-16 TR TR2001/02110T patent/TR200102110T2/xx unknown
- 2000-02-16 BR BR0008276-7A patent/BR0008276A/pt not_active Application Discontinuation
- 2000-02-16 RU RU2001124599/15A patent/RU2249454C2/ru not_active IP Right Cessation
- 2000-02-16 NZ NZ513526A patent/NZ513526A/xx not_active IP Right Cessation
- 2000-02-16 SK SK1184-2001A patent/SK11842001A3/sk not_active Application Discontinuation
- 2000-02-17 MY MYPI20000586A patent/MY126768A/en unknown
-
2001
- 2001-06-29 ZA ZA200105391A patent/ZA200105391B/en unknown
- 2001-08-15 US US09/930,337 patent/US20020103260A1/en not_active Abandoned
- 2001-08-16 NO NO20013987A patent/NO20013987D0/no not_active Application Discontinuation
-
2002
- 2002-03-27 HK HK02102380A patent/HK1042429A1/xx not_active IP Right Cessation
-
2003
- 2003-11-20 US US10/718,209 patent/US20040101487A1/en not_active Abandoned
-
2005
- 2005-08-03 US US11/196,560 patent/US20050287079A1/en not_active Abandoned
-
2009
- 2009-10-19 US US12/581,532 patent/US20100034890A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0008276A (pt) | Combinações de formoterol e propionato de fluticasona para asma | |
BR0008699A (pt) | Combinações de formoterol e furoato demometasona para asma | |
BR0008039A (pt) | Combinações de formoterol e um sal de tiotrópio | |
TW329387B (en) | Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate | |
PT1326595E (pt) | Composicao farmaceutica compreendendo resveratrol para o tratamento de disturbios respiratorios inflamatorios | |
BR0307050A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal | |
MY127980A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
BR9706822A (pt) | Composição kit processo para tratamento de um distúrbio respiratório e utilização da composição do kit de formoterol de um sal ou solvato farmaceuticamente aceitável do mesmo e de budesonida | |
MY127812A (en) | New use for budesonide and formoterol | |
SE9704833D0 (sv) | New formulation | |
BR0209992A (pt) | Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias | |
HUP0104410A2 (hu) | Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények | |
WO2002017894A3 (en) | Pharmaceutical formulation of salmeterol and fluticasone propionate | |
WO2005011602A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease | |
WO2001028535A3 (en) | Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate | |
WO2005011615A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | |
BR122014030158B8 (pt) | formulação farmacêutica | |
IL165574A0 (en) | Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases | |
ECSP003350A (es) | Combinaciones de un agonista de beta- 2- y un esteroide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL: A61K 31/135, A61P 11/00 Ipc: A61K 31/167 (2009.01), A61K 31/575 (2009.01), A61P |
|
B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: REFERENTE A PETICAO NAO CONHECIDA 020090119956 DE 22/12/2009 RJ |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |